A study of 300 million Epic records at the AAO meeting found an early risk signal flipped once diabetes, blood pressure and cholesterol were accounted for.
Recap by typeshit. Full story at Newswise.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
Novo says patients looked about two to three years younger on proteomic clocks across 10,052 people. Aging clock pioneer Steve Horvath calls it a strong effect.
She says people on GLP-1s often skip ordering when they aren't hungry, and explains why she sees that as a problem when eating out.
Loading…